In short
Clinical trials are studying Ly4100511 in adults with moderate-to-severe plaque psoriasis. The main goal is to compare different dose regimens with placebo and measure how well the treatment works and how many people improve. These studies help show whether Ly4100511 may be useful for this skin condition.
Key points
- Clinical trials of Ly4100511 are being done in adults with moderate-to-severe plaque psoriasis. The main study found in the trial data is a Phase 2 dose-ranging trial that compared multiple dose regimens with placebo. The study looked at whether participants reached PASI 75 by Week 12, which means a strong improvement in psoriasis severity. The trial enrolled 191 people and is now completed. Overall, the available trial data focus on whether Ly4100511 may help control plaque psoriasis in adult patients.
Trial overview
The available trial data show one Phase 2 study of Ly4100511 in adults with moderate-to-severe plaque psoriasis. The study was designed to compare several dose regimens of Ly4100511 with placebo in people who had this skin condition.
Study design and treatment groups
This was an interventional trial, which means researchers assigned participants to study treatment groups rather than just observing them. The trial included placebo tablets and Ly4100511 tablets taken by mouth, and the placebo was made to look the same as the active tablets. The study was also described as a dose-ranging study, meaning it tested multiple dose regimens to compare their effects.
Who could join the study
The study population was adult participants with moderate-to-severe plaque psoriasis. No other participant groups were listed in the trial data, so the main target population was adults with this form of psoriasis.
What was measured
The main endpoint was the proportion of participants achieving PASI 75 at Week 12. PASI 75 means a 75% improvement in the psoriasis severity score, so this endpoint checks how many people had a strong improvement after 12 weeks. The study summary says the goal was to compare the efficacy of multiple dose regimens of Ly4100511 versus placebo.
Trial status and size
The trial is listed as completed, which means the study has finished and the data have been collected. It enrolled 191 participants.